Your browser doesn't support javascript.
loading
Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease.
Alrouji, Mohammed; Al-Kuraishy, Haydar M; Al-Gareeb, Ali I; Alshammari, Mohammed S; Alexiou, Athanasios; Papadakis, Marios; Bahaa, Mostafa M; Batiha, Gaber El-Saber.
Afiliación
  • Alrouji M; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
  • Al-Kuraishy HM; Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
  • Al-Gareeb AI; Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
  • Alshammari MS; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
  • Alexiou A; University Centre for Research & Development, Chandigarh University, Mohali, Punjab, India.
  • Papadakis M; Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.
  • Bahaa MM; Department of Research & Development, Funogen, Athens, Greece.
  • Batiha GE; Department of Research & Development, AFNP Med, Wien, Austria.
J Cell Mol Med ; 28(11): e18412, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38842132
ABSTRACT
Cyclin-dependent kinase 5 (Cdk5) is a protein expressed in postmitotic neurons in the central nervous system (CNS). Cdk5 is activated by p35 and p39 which are neuron regulatory subunits. Cdk5/p35 complex is activated by calpain protease to form Cdk5/p35 which has a neuroprotective effect by regulating the synaptic plasticity and memory functions. However, exaggerated Cdk5 is implicated in different types of neurodegenerative diseases including Parkinson disease (PD). Therefore, modulation of Cdk5 signalling may mitigate PD neuropathology. Therefore, the aim of the present review was to discuss the critical role of Cdk5 in the pathogenesis of PD, and how Cdk5 inhibitors are effectual in the management of PD. In conclusion, overactivated Cdk5 is involved the development of neurodegeneration, and Cdk5/calpain inhibitors such as statins, metformin, fenofibrates and rosiglitazone can attenuate the progression of PD neuropathology.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Quinasa 5 Dependiente de la Ciclina Límite: Animals / Humans Idioma: En Revista: J Cell Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Quinasa 5 Dependiente de la Ciclina Límite: Animals / Humans Idioma: En Revista: J Cell Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido